Home > Dermatology > EADV 2020 > Upcoming Treatments > Meaningful sleep improvement with IL-13 inhibition

Meaningful sleep improvement with IL-13 inhibition

Presented By
Prof. Jonathan Silverberg, George Washington University, USA
EADV 2020
Phase 3, ECZTRA
A post-hoc analysis of the pivotal phase 3 ECZTRA 1 and 2 trials on tralokinumab treatment for atopic dermatitis observed early and significant ameliorations in various sleep assessing tools. Tralokinumab is an anti-IL-13 monoclonal antibody that has previously demonstrated significant superior efficacy in reducing signs and symptoms of atopic dermatitis (AD) in the pivotal phase 3 trials ECZTRA 1 (NCT03131648) and ECZTRA 2 (NCT03160885) [1]. As sleep loss plays a major role in the decreased quality of life of AD patients, Prof. Jonathan Silverberg (George Washington University School of Medicine and Health Sciences, USA) and his fellow researchers performed a post-hoc analysis of these studies with a focus on the impact of tralokinumab on sleep lo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on